Financial Performance - The company's operating revenue for 2022 was CNY 3,033,265,859.73, a decrease of 19.84% compared to 2021[19]. - Net profit attributable to shareholders increased by 32.75% to CNY 359,351,666.79, primarily due to investment income from the transfer of 51% equity in Jiuzhitang Medicine[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 50.85% to CNY 118,359,011.91, impacted by declining revenue and increased R&D expenses[19]. - The net cash flow from operating activities increased by 36.41% to CNY 499,132,759.89[19]. - Basic earnings per share rose by 32.55% to CNY 0.4198[19]. - Total assets at the end of 2022 were CNY 5,238,415,577.39, a slight decrease of 0.52% from the previous year[19]. - The net assets attributable to shareholders increased by 0.42% to CNY 3,985,715,529.20[19]. - The company reported a weighted average return on equity of 9.10%, an increase of 2.19% from 2021[19]. - The company reported a total revenue of CNY 458,366,951.02 and a net profit of CNY 46,888,391.01 from its subsidiary Jizhitang Pharmaceutical Trading Co., Ltd.[94]. - The company reported a total revenue of 263.88 million in 2022, with a net profit of 221.42 million, indicating a significant performance in the fiscal year[123]. Equity Transfer and Investments - The company completed the transfer of 51% equity in Jiuzhitang Medicine in May 2022, which significantly affected the financial results[19]. - The company signed a framework agreement to transfer 51% of its stake in Jiuzhitang Medicine to Yifeng Pharmacy, aiming to optimize business structure and improve resource allocation efficiency[51]. - The company transferred 51% of its stake in Hunan Jizhitang Pharmaceutical Co., Ltd. for CNY 20,400,000, resulting in a gain of CNY 26,830.48 million due to the loss of control over the subsidiaries[96]. - The company has not made any significant equity investments during the reporting period[86]. Research and Development - The company is actively pursuing R&D initiatives to innovate and improve its product line, aligning with national strategies for the pharmaceutical industry[32]. - The R&D investment as a percentage of operating income rose to 4.69%, up from 3.11% in the previous year[77]. - The number of R&D personnel increased by 1.23% to 329, with a notable rise in the proportion of personnel holding doctoral degrees[76]. - The company is investing 100 million yuan in R&D for new technologies aimed at enhancing product efficiency[133]. - The company is committed to enhancing team building and talent development to improve professional capabilities and management skills[107]. Market Position and Strategy - The company is positioned in the pharmaceutical industry, focusing on traditional Chinese medicine, which is supported by national policies promoting innovation and development in this sector[30]. - The company plans to expand its market presence and product offerings in response to increasing demand for preventive healthcare and traditional medicine[31]. - The company has established a first-tier product lineup including Shuxuetong Injection, Liuwei Dihuang Pill, and An Gong Niu Huang Wan, among others[36]. - The company is actively pursuing mergers and acquisitions to bolster its market position and operational capabilities[127]. - The company aims to integrate traditional medicine with precision medicine, focusing on health management across prevention, treatment, and rehabilitation[101]. Regulatory Compliance and Governance - The company emphasizes transparent information disclosure, adhering to legal regulations and ensuring timely and accurate communication with investors[118]. - The board of directors and supervisory board are elected following strict legal and procedural guidelines, ensuring responsible governance[119]. - The company has established specialized committees within the board to ensure effective governance and oversight[119]. - The company has a clear ownership structure regarding its assets, ensuring no ambiguity in its relationship with the controlling shareholder[119]. - The company has maintained compliance with all commitments made by its actual controllers and shareholders, ensuring no competitive activities with Jizhitang[192]. Environmental Management - The company has established environmental management systems and has complied with various environmental protection laws and regulations, ensuring that major pollutants are discharged within standards[162]. - The company’s Changsha production bases have passed environmental protection acceptance checks, with the main pollutants meeting discharge standards[163]. - The company has implemented the "three simultaneous" system for environmental protection in its production projects, ensuring compliance with environmental measures[164]. - The company has established a regulatory compliance framework for periodic discharge monitoring[177]. - The company is committed to reducing emissions and improving environmental performance in line with regulatory standards[173]. Employee Management and Compensation - The total number of employees at the end of the reporting period is 3,416, with 2,054 from the parent company and 1,362 from major subsidiaries[142]. - The company has established a talent market compensation incentive mechanism to attract and retain necessary talent[144]. - The independent directors' compensation is set at 120,000 yuan per year, reflecting the company's commitment to governance[134]. - The company has implemented a performance-based bonus system for senior management, with bonuses distributed semi-annually based on individual performance[134]. - The employee training plan focuses on professional and comprehensive quality development, aligning employee career growth with the company's strategic goals[145]. Future Outlook - The company is optimistic about future growth prospects, with guidance indicating potential revenue increases in the upcoming fiscal year[123]. - The company has set a revenue guidance of 1.5 billion yuan for the next fiscal year, indicating an expected growth of 25%[133]. - Market expansion plans include entering three new provinces, projected to increase market share by 10%[133]. - The company aims to maintain its commitment to environmental sustainability while pursuing growth opportunities[174].

九芝堂股份有限公司 2023 年第一季度报告 2023 年第一季度报告 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 1 | --- | --- | --- | --- | |------------------------------------------------------|------------------|------------------|--------------------------------| | □是 否 | 本报告期 | 上年同期 | 本报告期比上年同期增减 （%） | | 营业收入（元） | 1,089,123,621.24 | 1,196,431,070.59 | -8.97% | | 归属于上市公司股东的净利 润（元） | 161,848,803.83 | 123,813,470.83 | 30.72% | | 归属于上市公司股东的扣除 非经常性损益的净利润 （元） | 159,925,483.45 | 113,738,602.57 | 40.61% | | 经营活动产 ...

证券代码：000989 证券简称：九芝堂 九芝堂股份有限公司投资者关系活动记录表 编号：20141030002 | --- | --- | --- | |----------|--------------------------|--------------------------------------------------------------------------------------| | | | | | 投资者关 | | √特定对象调研 □分析师会议 | | 系活动类 | □媒体采访 □业绩说明会 | | | 别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位 | | 交银施罗德基金庄琰、银河基金余科苗、易方达基金曾金晶、泰信基金徐慕浩、申万菱信基金 | | 名称及人 | | 季新星、浙商证券杜永宏、中航证券沈文文、上投摩根基金李朝伟、东吴证券许希晨、博睿财智 | | 员姓名 | | 邓飞、子竹资本杨彦哲、长信基金安昀、兴业资管匡伟、华商基金彭欣杨、国金证券资产管理姜 | | | | 英、华夏基金刘志军、 ...

证券代码：000989 证券简称：九芝堂 编号：20170511002 九芝堂股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------|-------------------------|----------------------------------------------------------------------------------| | | | | | 投资者关系 | √ | 特定对象调研 □分析师会议 | | 活动类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名 | | 新华基金赵强、中信证券陆银波、唐嘉奕、李晓菲、鑫舵资产杨西媛、达麟资产张景峰、辰 | | 称及人员姓 | | 能风投伊喆、李威、银河证券霍辰伊、李平祝、壹玖资产郑森峰、长盛基金吴博文、中信产 | | 名 | | 业基金宋林峰、上海宏铭投资刘懿、亦庄国投赵海娇、李翠莲、新华汇嘉戴泽龙、道仁资产 | | | | 姚宏福、恒天明泽赵群涛、原点正则贰 ...

证券代码：000989 证券简称：九芝堂 编号：20170509001 九芝堂股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |------------|------------------------|--------------------------------------------------------------------------------|---------------------------| | 投资者关系 | √ | 特定对象调研 □分析师会议 | | | 活动类别 | □ | 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | □ | 其他 （请文字说明其他活动内容） | | | 参与单位名 | | 汇丰银行赵智捷、温馨，远望资产王超俊，长城国际叶天衡， | RAYS 许泰然 | | 称及人员姓 | | | | | 名 | | | | | 时间 | 2017 年 5 月 9 | 日上午 8:45-9:45 | | | 地点 | 公司二楼会议室 | | | | 上市公司接 | ...

证券代码：000989 证券简称：九芝堂 编号：20191114001 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------|-------------------------|---------------------------------|----------------------|-------|-------|-------|-------|----------------------------------------------------------------------|---------| | | | | | | | | | | | | 投 资 者 关 系 | √ | 特定对象调研 □分析师会议 | | | | | | | | | 活动类别 | □ | 媒体采访 □业绩说明会 | | | | | | | | | | □新闻发布会 □路演活动 | | | | | | | | | | | □ 现场参观 | | | | | | | | | | | □ | 其他 （请文字说明其他活动内容） ...